QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:OCX

OncoCyte (OCX) Stock Forecast, Price & News

$3.20
+0.07 (+2.24%)
(As of 09/28/2023 ET)
Compare
Today's Range
$3.08
$3.29
50-Day Range
$3.13
$4.03
52-Week Range
$3.08
$16.00
Volume
2,519 shs
Average Volume
19,091 shs
Market Capitalization
$26.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.31

OncoCyte MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
128.5% Upside
$7.31 Price Target
Short Interest
Bearish
2.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of OncoCyte in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.09) to ($3.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

840th out of 969 stocks

Diagnostic Substances Industry

10th out of 13 stocks


OCX stock logo

About OncoCyte (NASDAQ:OCX) Stock

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OCX Price History

OCX Stock News Headlines

OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com
OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com
Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Investing Legend Warns: NVIDIA is a "Delusion"
Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.
Oncocyte Reports Second Quarter 2023 Financial Results
Oncocyte Announces 1-For-20 Reverse Stock Split
OCX - OncoCyte Corporation
Oncocyte Begins Manufacturing Transplant Blood Test
See More Headlines
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Company Calendar

Last Earnings
8/10/2023
Today
9/28/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCX
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.31
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$4.25
Forecasted Upside/Downside
+128.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-72,900,000.00
Pretax Margin
-1,472.21%

Debt

Sales & Book Value

Annual Sales
$960,000.00
Cash Flow
$0.89 per share
Book Value
$5.78 per share

Miscellaneous

Free Float
8,081,000
Market Cap
$26.37 million
Optionable
Optionable
Beta
1.58
10 Best Stocks to Own in 2023 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joshua Riggs (Age 40)
    Pres, CEO & Director
    Comp: $373.2k
  • Mr. James Liu (Age 27)
    Sr. Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer
    Comp: $192.48k
  • Mr. Yuh-Min Chiang Ph.D.
    Chief Technology Officer
  • Dr. Ekkehard Schutz M.D.
    Ph.D., Chief Science Officer
  • Ms. Sandra O'Donald
    Sr. VP of Bus. Operations
  • Dr. Michael D. West Ph.D. (Age 70)
    Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.
  • Peter Hong
    Sec.
  • Ms. Sara Riordan
    Director of Medical Education













OCX Stock - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OCX shares.
View OCX analyst ratings
or view top-rated stocks.

What is OncoCyte's stock price forecast for 2023?

4 Wall Street analysts have issued 1 year target prices for OncoCyte's stock. Their OCX share price forecasts range from $4.25 to $10.00. On average, they anticipate the company's share price to reach $7.31 in the next twelve months. This suggests a possible upside of 128.5% from the stock's current price.
View analysts price targets for OCX
or view top-rated stocks among Wall Street analysts.

How have OCX shares performed in 2023?

OncoCyte's stock was trading at $6.4180 at the beginning of 2023. Since then, OCX stock has decreased by 50.1% and is now trading at $3.20.
View the best growth stocks for 2023 here
.

When is OncoCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our OCX earnings forecast
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) issued its earnings results on Thursday, August, 10th. The company reported ($1.07) EPS for the quarter, topping the consensus estimate of ($2.60) by $1.53. The company earned $0.46 million during the quarter, compared to analysts' expectations of $0.60 million.

When did OncoCyte's stock split?

Shares of OncoCyte reverse split on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OncoCyte own?
What is OncoCyte's stock symbol?

OncoCyte trades on the NASDAQ under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a variety of institutional and retail investors. Top institutional investors include AWM Investment Company Inc. (172.16%), Pura Vida Investments LLC (165.35%), Geode Capital Management LLC (14.91%), BlackRock Inc. (14.71%), Renaissance Technologies LLC (1.68%) and LPL Financial LLC (1.55%). Insiders that own company stock include Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends
.

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $3.20.

How much money does OncoCyte make?

OncoCyte (NASDAQ:OCX) has a market capitalization of $26.37 million and generates $960,000.00 in revenue each year.

How can I contact OncoCyte?

OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.

This page (NASDAQ:OCX) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -